Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abiomed Inc (NQ: ABMD )

238.65 -1.81 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 637,255
Open 239.30
Bid (Size) 238.38 (1)
Ask (Size) 350.00 (2)
Prev. Close 240.46
Today's Range 237.57 - 243.76
52wk Range 227.25 - 376.99
Shares Outstanding 45,516,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes
From Abiomed
Via Business Wire
Recap: Abiomed Q4 Earnings
Abiomed (NASDAQ:ABMD) reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-34.85%
-34.85%
1 Month
-26.21%
-26.21%
3 Month
-22.29%
-22.29%
6 Month
-29.85%
-29.85%
1 Year
-12.90%
-12.90%

More News

Read More
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
From Abiomed, Inc.
Via Business Wire
A Preview Of Abiomed's Earnings
Via Benzinga
What 4 Analyst Ratings Have To Say About Abiomed
Via Benzinga
Recap: Abiomed Q3 Earnings
Via Benzinga
Earnings Scheduled For February 3, 2022
Via Benzinga
World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
From Abiomed
Via Business Wire
Markets Rise Despite Another New 2-Year High For US 10-Year Treasury Note
Via Benzinga
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
First Patient in Japan Treated with Impella 5.5 with SmartAssist
From Abiomed, Inc.
Via Business Wire
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
Via InvestorPlace
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
From Abiomed, Inc.
Via Business Wire
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Abiomed's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Via Benzinga
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
From Abiomed, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
Via Benzinga
Ominous Death Cross Forms On Abiomed's Chart
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
From Abiomed, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
From Abiomed, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.